罗沙司他治疗尿毒症肾性贫血对患者生化指标及血清CRP水平的影响  

Effect of Roxastat in the treatment of uremic renal anemia on biochemical indexes and serum CRP levels

作　　者：杨红丽 陈冬梅[1] 房星星[1] 沈燕[1] 沈良兰[1] YANG Hongli;CHEN Dongmei;FANG Xingxing;SHEN Yan;SHEN Lianglan(Department ofNephrology,The Second Affiliated Hospital ofNantong University,Nantong 226000,Jiangsu,China)

机构地区：[1]南通大学第二附属医院肾内科,江苏南通226000

出　　处：《现代医学与健康研究电子杂志》2020年第17期8-11,共4页Modern Medicine and Health Research

摘　　要：目的研究罗沙司他治疗尿毒症肾性贫血对患者生化指标及血清CRP水平的影响。方法回顾性分析2019年1月至12月在南通大学第二附属医院行维持性血液透析治疗的46例尿毒症肾性贫血患者的临床资料,按治疗方法不同可分为A组(21例)和B组(25例),A组患者给予重组人促红素注射液治疗,B组患者给予罗沙司他治疗,1周为1个疗程,两组患者均治疗12周。比较两组患者治疗4周、8周、12周后红细胞指标RBC、Hb、Het,△Hbmax值,生化指标SF、叶酸、维生素B^,CHOL、TG、LDL、CRP水平变化;统计两组患者治疗期间不良反应发生情况。结果与治疗前相比,治疗4周、8周、12周后两组患者RBC、Hb、Het水平均呈逐渐升高趋势,治疗8周、12周后B组患者RBC水平高于A组;对RBC、Hb、Het进行单因素方差分析显示,随治疗时间的延长其值逐渐升高;B组患者△Hbmax值高于A组,治疗12周内B组患者的Hb均有不同程度升高,且升高值达20 g/L以上者占比达52.00%,明显高于A组的9.52%;两组患者铁蛋白、TG、LDL均较治疗前下降,且B组低于A组;治疗4~12周后B组患者血清CRP呈下降趋势,治疗12周后B组低于A组(均P<0.05),A组与B组患者不良反应总发生率比较,差异无统计学意义(P>0.05)„结论罗沙司他可以显著改善尿毒症患者肾性贫血,诱导红细胞生成,促进铁元素的吸收,且不受炎症状态的影响,安全性良好。Objective To study the effect of rosaxastat in the treatment of uremic renal anemia on biochemical indicators and serum CRP levels.Methods A retrospective analysis of the clinical data of 46 patients with uremic renal anemia who underwent maintenance hemodialysis at the Second Affiliated Hospital of Nantong University from January to December 2019,they were divided into group A(21 cases)and group B(25 cases)according to the different treatment methods.Patients in group A were treated with recombinant human erythropoietin injection,group B was treated with rosastat,1 week was a course of treatment,and patients in both groups were treated for 12 courses.Compare the red blood cell indicators RBC,Hb,Het,△Hbmax,biochemical indicators SF,folic acid,vitamin B^,CHOL,TG,LDL,CRI*and safety and adverse events during treatment between the two groups of patients after 4 weeks,8 weeks and 12 weeks of treatment.Results Compared with before treatment,the RBC,Hb,and Het levels of the two groups of patients gradually increased after 4 weeks,8 weeks and 12 weeks.After 8 weeks and 12 weeks of treatment,group B was higher than group A.After 4 weeks of treatment,the RBC level in group B was lower than group A,and Hb and Het levels in group B were higher than group A;A one-way analysis of variance of RBC,Hb,and Het showed that,it gradually increased with the extension of treatment time;The hemoglobin of patients in group B of A Hbmax value increased higher than that of group A,and the hemoglobin of patients in group B increased to varying degrees within 12 weeks of treatment,and the increase of 20 g/L or more accounted for 52.00%,which was significantly higher 9.52%in group A;The ferritin,TG,LDL of the two groups of patients were all decreased,and the group B was lower than that of the group A(all P<0.05).There was no significant difference in adverse reactions between group A and group B(P>0.05).Conclusion Roxastat can significantly improve renal anemia in patients with uremia,induce red blood cell production,promote iron absorption

关 键 词：尿毒症 肾性贫血 罗沙司他 血红蛋白 生化指标 C-反应蛋白 

分 类 号：R692.5[医药卫生—泌尿科学]